HALAL TRADING ROOM

Sharia-screened signals
GL

GLAXF

GSK plc
$23.51-6.72% today
Sharia status
COMPLIANT
Per our secondary compliance provider · assessed 2026-07-31
Purification 0.19%HTR non-permissible income 0.17%
Methodology breakdown (7/7 compliant)▾
AAOIFI ● PASS ▾
Debt ratio 19.4% (< 30%)
Investments ratio 4.6% (< 30%)
Non permissible income ratio 0.2% (< 5%)
Usmani ● PASS ▾
Debt ratio 23.6% (< 33%)
Investments ratio 5.6% (< 33%)
Nonliquid assets ratio 82.2% (< 20%)
Non permissible income ratio 0.2% (< 5%)
Net liquid assets -$14.2B (mkt cap $100.1B)
Dow Jones ● PASS ▾
Debt ratio 21.2% (< 33%)
Cash and interest ratio 5.0% (< 33%)
Receivables ratio 10.9% (< 33%)
Non permissible income ratio 0.2% (< 5%)
S&P Shariah ● PASS ▾
Debt ratio 22.3% (< 33%)
Cash and interest ratio 5.2% (< 49%)
Receivables ratio 11.5% (< 49%)
Non permissible income ratio 0.2% (< 5%)
MSCI ● PASS ▾
Debt ratio 23.6% (< 33%)
Cash and interest ratio 5.6% (< 33%)
Receivables ratio 17.8% (< 33%)
Non permissible income ratio 0.2% (< 5%)
MSCI M ● PASS ▾
Debt ratio 22.3% (< 33%)
Cash and interest ratio 5.2% (< 33%)
Receivables ratio 16.8% (< 49%)
Non permissible income ratio 0.2% (< 5%)
FTSE ● PASS ▾
Debt ratio 23.6% (< 33%)
Cash and interest ratio 5.6% (< 33%)
Receivables ratio 17.8% (< 50%)
Non permissible income ratio 0.2% (< 5%)

Business activity cleared — no excluded categories detected

🔎 Data provenance — sourcing & safeguards behind these numbers

Source: stored filing inputs · Balance sheet as of 2025-12-31 · Income statement as of 2025-12-31

Real XBRL tags pulled from the issuer's own filing:
Total assets Assets
Debt Borrowings
Total liabilities Liabilities
Investments CashAndCashEquivalents
Current liabilities CurrentLiabilities
Receivables TradeAndOtherCurrentReceivables
Total revenue Revenue
Interest income InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost
Finance costs FinanceCosts
Currency conversions applied:
Assets: 61,118,000,000 GBP → $82,301,498,800 (rate 1.3466 on 2025-12-31)
Borrowings: 14,453,000,000 GBP → $19,462,409,800 (rate 1.3466 on 2025-12-31)
Liabilities: 45,162,000,000 GBP → $60,815,149,200 (rate 1.3466 on 2025-12-31)
CashAndCashEquivalents: 3,397,000,000 GBP → $4,574,400,200 (rate 1.3466 on 2025-12-31)
CurrentLiabilities: 21,391,000,000 GBP → $28,805,120,600 (rate 1.3466 on 2025-12-31)
TradeAndOtherCurrentReceivables: 7,471,000,000 GBP → $10,060,448,600 (rate 1.3466 on 2025-12-31)
Revenue: 32,667,000,000 GBP → $43,060,593,035 (rate 1.3182 on 2025-01-01..2025-12-31)
InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost: 56,000,000 GBP → $73,817,406 (rate 1.3182 on 2025-01-01..2025-12-31)
FinanceCosts: 701,000,000 GBP → $924,035,746 (rate 1.3182 on 2025-01-01..2025-12-31)
🕌Open research, not a fatwa — verify with your own scholar.
Trade setup SEPARATE FROM SHARIAH
🟠 NOT YET
The main driver: lagging the market by 7.8%. More negatives than positives right now. The setup isn't ready — check...
33
of 100
Setup confidence — system conviction, not win probabilityF
Why this signal?
Structure0 of 2 timeframes bullish · 100.0% aligned
VolumeRelative volume 0.3× the 20-day average
Momentum10-day rate of change -5.9%
Overall readNOT YET

GSK plc (GLAXF) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-07-31). See the full ratio breakdown and business-activity screen below for the reasoning.

Market & analysts
Wall Street consensus
HOLD
32 analysts
Institutional own.
48.3%
of shares
Momentum (10d)
-5.9%
rate of change
SMC grade
F · 33
100.0% aligned
COMPLIANT
Sharia compliance
0.19%
Purification ratio
0.17%
Non-permissible income — HTR, from filings (2025-12-31)
F · 33
SMC grade — 100.0% timeframe alignment
-5.9%
Rate of change (10d)
HOLD
Wall Street consensus (32)
48.3%
Institutional ownership

🕌 In-house Compliance Research

Research only, not the primary verdict above — computed from SEC EDGAR filings and business-activity classification, same as the Discord bot's !halal command.

Business activity: cleared (no excluded categories detected)

AAOIFI Standard 21 (% of market cap) — Pass
Debt ratio 19.4% (< 30%)
Investments ratio 4.6% (< 30%)
Non permissible income ratio 0.2% (< 5%)
Usmani (% of total assets) — Pass
Debt ratio 23.6% (< 33%)
Investments ratio 5.6% (< 33%)
Nonliquid assets ratio 82.2% (< 20%)
Non permissible income ratio 0.2% (< 5%)
Net liquid assets -$14.2B (mkt cap $100.1B)
Dow Jones Islamic Market (% of 24-mo avg market cap) — Pass
Debt ratio 21.2% (< 33%)
Cash and interest ratio 5.0% (< 33%)
Receivables ratio 10.9% (< 33%)
Non permissible income ratio 0.2% (< 5%)
S&P Shariah Indices (% of 36-mo avg market cap) — Pass
Debt ratio 22.3% (< 33%)
Cash and interest ratio 5.2% (< 49%)
Receivables ratio 11.5% (< 49%)
Non permissible income ratio 0.2% (< 5%)
MSCI Islamic Index (% of total assets) — Pass
Debt ratio 23.6% (< 33%)
Cash and interest ratio 5.6% (< 33%)
Receivables ratio 17.8% (< 33%)
Non permissible income ratio 0.2% (< 5%)
MSCI Islamic M-Series (% of 36-mo avg market cap) — Pass
Debt ratio 22.3% (< 33%)
Cash and interest ratio 5.2% (< 33%)
Receivables ratio 16.8% (< 49%)
Non permissible income ratio 0.2% (< 5%)
FTSE Shariah Global Equity Index Series (% of total assets) — Pass
Debt ratio 23.6% (< 33%)
Cash and interest ratio 5.6% (< 33%)
Receivables ratio 17.8% (< 50%)
Non permissible income ratio 0.2% (< 5%)
🔎 Data provenance — sourcing & safeguards behind these numbers

Source: stored filing inputs · Balance sheet as of 2025-12-31 · Income statement as of 2025-12-31

Real XBRL tags pulled from the issuer's own filing (auditable against it directly):
Total assets Assets
Debt Borrowings
Total liabilities Liabilities
Investments CashAndCashEquivalents
Current liabilities CurrentLiabilities
Receivables TradeAndOtherCurrentReceivables
Total revenue Revenue
Interest income InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost
Finance costs FinanceCosts
Currency conversions applied (real point-in-time/period-average rates, not today's rate applied retroactively):
Assets: 61,118,000,000 GBP → $82,301,498,800 (rate 1.3466 on 2025-12-31, via Frankfurter.app (ECB reference rates))
Borrowings: 14,453,000,000 GBP → $19,462,409,800 (rate 1.3466 on 2025-12-31, via Frankfurter.app (ECB reference rates))
Liabilities: 45,162,000,000 GBP → $60,815,149,200 (rate 1.3466 on 2025-12-31, via Frankfurter.app (ECB reference rates))
CashAndCashEquivalents: 3,397,000,000 GBP → $4,574,400,200 (rate 1.3466 on 2025-12-31, via Frankfurter.app (ECB reference rates))
CurrentLiabilities: 21,391,000,000 GBP → $28,805,120,600 (rate 1.3466 on 2025-12-31, via Frankfurter.app (ECB reference rates))
TradeAndOtherCurrentReceivables: 7,471,000,000 GBP → $10,060,448,600 (rate 1.3466 on 2025-12-31, via Frankfurter.app (ECB reference rates))
Revenue: 32,667,000,000 GBP → $43,060,593,035 (rate 1.3182 on 2025-01-01..2025-12-31, via Frankfurter.app (ECB reference rates))
InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost: 56,000,000 GBP → $73,817,406 (rate 1.3182 on 2025-01-01..2025-12-31, via Frankfurter.app (ECB reference rates))
FinanceCosts: 701,000,000 GBP → $924,035,746 (rate 1.3182 on 2025-01-01..2025-12-31, via Frankfurter.app (ECB reference rates))

Combined verdict: AAOIFI Compliant Usmani Compliant Dow Jones Islamic Compliant S&P Shariah Compliant MSCI Islamic Compliant MSCI Islamic M Compliant FTSE Shariah Compliant

31.1928.1225.0421.9618.892025-09-112026-03-122026-09-10

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
22.19
S2
22.85
S1
23.18
PIVOT
23.84
R1
24.17
R2
24.83
R3
25.16

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

7-day expected range
24.2882 – 25.6678
±2.76% from 24.978, made 2026-09-03 · resolves 2026-09-10
STRONG SELL
from 19 indicators
Not enough resolved predictions yet — 0 of 10 needed before we publish an accuracy figure. 21747 forecast(s) are currently open and will be scored automatically when their horizon expires.

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

Technical Summary

STRONG SELL
19 indicators
OscillatorsSTRONG SELL
1 buy · 3 neutral · 3 sell
Moving averagesSTRONG SELL
0 buy · 0 neutral · 12 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)39.30NEUTRAL
Stochastic %K (14)22.27NEUTRAL
CCI (20)-180.28BUY
Williams %R (14)-77.73NEUTRAL
MACD (12,26,9)-0.13SELL
ROC (10)-2.44SELL
Momentum (10)-0.60SELL
EMA (10)24.74SELL
SMA (10)24.95SELL
EMA (20)24.99SELL
SMA (20)25.10SELL
EMA (30)25.11SELL
SMA (30)25.15SELL
EMA (50)25.26SELL
SMA (50)25.39SELL
EMA (100)25.41SELL
SMA (100)25.51SELL
EMA (200)24.90SELL
SMA (200)25.71SELL

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

About GSK plc

Healthcare · Drug Manufacturers - General

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.

gsk.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Verdict

🟠 NOT YET

The main driver: lagging the market by 7.8%. More negatives than positives right now. The setup isn't ready — check back when the trend or RSI changes.

Scores: 1 bullish / 2 bearish

Grade verdict

No real edge — avoid

SMC — Top Down

TimeframeBiasBars
📅 Daily BEARISH 26
⏲ 5-Min BEARISH 27

Momentum & Volume

Insider Activity (90d)

NO DATA   0 buys · 0 sells

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

NEUTRAL   report date 2026-09-01 · Asset managers net 934180 (-19048)

Key Statistics

$18.99 – $31.48
52-week range
39
RSI
4/10
Risk score

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.

Tell us what's working, what's confusing, or what you want to see next — read by a real person, not a form that goes nowhere.